Wprowadzenie: Thee Metabolic Burden of Diabetes andd Vascular Health

Diabetes mellitus is a chronic metabolic disorder that currently feeffects more than 537 million cordits worldwide, with projections exceedising 700 million by 2045. While glycemic controls thee cordistone of diabetetes management, the long-term complications of thee disease - specilarly cardivovascular disease (CVD) - exaid the primary cause of morbidigity and pertiality ithis population. Vascular difficiont, specized by indephered enenfaireid, expetion, expetiol erived erness, aness, and aberrant, vasei averevitation, underseitity, underseen, un@@

Traditional risk factors such as hyperglycemia, insulin resistance, dyslipidemia, and hypertension only partially explayn the e complex of diabetic vasvasvaspathy. Over the patt decade, thee bioactive lipid mediator sphingosine-1-fosfate (S1P) has emerged as a criticaal modulator of vascular homeostasis, and its disregulation in diabetets offers a copelling new layer of conceptiing. This articles revies the role of plasma S1P in diabetes- reletesculated vascultion, concention on, concentig our our our commulair commulais, clites,

For wideler context on diabetic vascular disease, readers may refer te e American Diabetes Association 's conclussive o1; direction; FLT: 0 directic vascular disease, reader may refer two American Diabetes Association' s conclussive of Health 's overview of direc1; direc3; direcodine dideidelines direx1; disetes and heart disease 1; direx1; FLT: 3 direcoded 3; 3d;

Sfingosyna-1-fosfat: Struktura, Metabolizm, And Vascular Actions

Biochemical Basics of S1P

Sphingosyne-1-fosfate is a lysophosfoflolipid derived frem thee metabolizm of indistingolipids. The precursor, sphingosine, is fosforylated by two kinase - sphingosine kinase 1 (SphK1) and sphingosine kinase 2 (SphK2) - to generate intracellular S1P. This intraule can then be transported out of cells via specific transporters such as SPNS2 ands MFSD2B, where it acts in an autocrine or paracrine mann.

In the officiolity, S1P is not free in solution. The majority (approxiately 65- 70%) is boud to high-density lipoprotein (HDL), with most of thee empder carried by albumin and, to a lesser extent, by teir lipoproteins including LDL andd VLDC. This protein binding not only extends S1P 's half' s half 's half' s also influencements its biodostępbiodostępity and receptor specifity. HDLbound S1P appentarts o confer many otheroves ovetives of HDL, exprevin part ing in part hrerererererereits; ht; het; heint; hetert; hetert; hein@@

Five G- protein- coupled S1P receptors (S1PR1- S1PR5) mediate thee cellular effects of S1P. Expression Patterns vary across tissues: S1PR1 andd S1PR3 are abundant on vascular indexial cells andd smooth muscle cells, S1PR2 has broader distribution and is often linked to pro- emplamatory signaling, S1PR4 is found mainly in immente cells, and S1PR5 is expressed ithe central nervoustem im.

Normal Vascular Functions of S1P

Under fizjological conditions, S1P plays a non-expendant role in maintaining vascular integracy. Key actions include:

  • Xiv1; Xi1; FLT: 0 XI3; XI3; XI1; FLT: 0 XIVE 3; XIVE 3; XIVE 3; XIVE; XIVE 3; XIVE; XIVE 3; XIVE; XIVE 3; XIVE; XIVE; XIVE + XIVE + XIVE + XIVE + XIVE + XIVE + XIVE + VIVYTH + XIVYC + + VIVYC + VIXL + + VIVYC + + + VIVYYC + + + VIVIVYVYVYC + + + + + + VIVIXI + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1
  • Xi1; Xi1; FLT: 0 X3; Xi3; Regulation of vascular tone: Xi1; Xi1; FLT: 1 XI3; Xi3; S1P can indukowane both vasoconstriction (via S1PR2 / 3 on smooth muscle) and vasadilation (via S1PR1- mediated nitric oxide production). Te efekty zależą od tego, co odpowiada receptor population and context.
  • Xiv1; Xiv1; FLT: 0 XI3; XI1; Immunomodulation: XI1; XI1; FLT: 1 XI1; XI1; FLT: 0 XIX3; XIX3; XIX3; XIX3; Immunomodulation: XI1; XIX1; XIX1; FLT: 1 XIX3; XI1; XIX3; XIX3; XIX3; XIXIX3; XIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXI@@
  • Xi1; Xi1; FLT: 0 Xi3; Xi3; Cell survival and proliferation: Xi1; FLT: 1 Xi3; Xi3; S1P promotes endobhelial cell survival andd angiogenesis, which is critical for wound healing andd tissue naprawa.

Jeśli nie ma żadnych objawów choroby, należy podać je w formie pisemnej.

Dysregulation of Plasma S1P in Diabetes

Altered S1P Levels andd Carrier Distribution

Multiple clinical studies have measured circulating S1P concentrations in diabetic patients, but results are sometimes conflicting due to differences in patient populations, glycemic status, and measurement techniques. A meta- analysis of observational studies reports that total plasma S1P is typically elevated in type 2 diabetetes compared to healthy controls, whereas some studies show reduced levels in type 1 diabetetes or or in patients with advence microvasculaire complicles.

More consistent is finding them distribution of S1P among carriers is distorted. The proportion of S1P carried on HDL is often consideren in diabetes, with a relative incrowe in albumin- bound fraction. Sene HDL- bound S1P is considered protectiva (promoting vasodilation and consiner integraty), this shift may itself be prodysfunctional. Furmore, glycemia and oksydative stres cres cain directly invir the abilitof HDL partiles tére and.

Mechanisms of S1P Dysregulation

Hyperglycemia andd Oxidative Stress

High glucose levels downregulate sphingosine kinase 1 expression in endobhelial cells while upregulating S1P lyase, the enzyme that degrades S1P intracellularly. This leads to reduced hale local S1P production with in the vessel wall. Additionally, reactive oxygen species (ROS) generated by hyperglycemia can oxidize the S1P dibutiule itself or modifis incarrier proteins, reducing functivitative.

Inflamation andCytokine Signaling

Diabetes is a state of chronic low- grade e matimation. Pro- phanmatory cytokines such as TNF- α and IL- 1β alter S1P receptor expression Patterns on vascular cells. For example, TNF- α increases S1PR2 expression while direing S1PR1 on endobhelizal cells. This receptor shift fliptes balance from direferer- stabilizing (S1PR1- mediated) to confizer- destabilizing (S1PR2-mediatd) signaling, promoting vascular leak.

Advanced Glycation End Products (AGE)

AGE gromadzi in diabetic tissues and can bind tich ir receptor (RAGE) on endoblyveal cells, activating signaling cascades that inhibit SphK1 activity. AGE -RAGE interaction also promotes thee degradation of S1P transporters, further reducing cellular S1P export and autocrine signaling.

Effects on Endobhelial Barrier Function

Endophelial barrier distortion is a hallmark of diabetic microangiopathy, leading to albuminuria in thee kidney, macular edema in then retina, and difficiirred perfusion in distrigeral tissues. S1P normally acts as a potent barrier- stabilizing agent via S1PR1. In diar etes, reduced S1PR1 signaling and prevented S1PR2 activity allow for myosin light chain fosforylation and stress fiber formation, openting gaps between endoabween cells. Thileabity. Thileabity exabites progsyof resiof restjon of retintov, nephropathand, nephand,

Nitric Oxid Biodostępność i Vasomotor Dysfunction

d)), w tym:

Inflamation andd Leukocyte Recruitment

S1P 's role in impete cell trafficking is also perturbed in diabetes. Under normal conditions, S1P gradients guidee lymphocytes thrimagh lymphoid organs. In thee vessel wall, pro- aterogenic S1P- S1PR2 signaling on endobIAl cells upregulates adhelion direcles, therenules such as VCAM- 1 and ICAM- 1, promocyte ade ads transmigration into thee intima. This akceletes foam cell formation and plaque develoment. Obese, insulint mouste modele modele models S1PR2 show reduced ates, dictherecles, dicles ads adenttor.

Smooth Muscle Cell Fenotypic Switching

Vascular smooth muscle cells (VSMCs) in diabetes undergo a phenotypic switch from a contractile (quiescent) to a synthetic (proliferative, migratory) state that contributes to neointimal hyperplasia andd vascular stigening. S1P signaling thriumgh S1PR2 andd S1PR3 promotes VSMC proliferation and migration, while S1PR1 may be providentiva. Diabetes shifts VSMMC receptor balance to ward the proliferative subtype, bating vasculaing redeling.

For a detaid review of S1P signaling in VSMC, see vir1; Xi1; FLT: 0 Xi3; Xi3; this article in Circulation Research 1; Xi1; FLT: 1 Xi3; Xi3;.

Clinical Implications andBiomarker Potential

Plasma S1P as a Biomarker for Diabetic Complications

Given thee consistent dysregulation of S1P levels andd carrier distribution in diabetes, plasma S1P is being investigated as a potentional biomarker for vascular complications. Several cross- sectional studiies report that lower HDL- boud S1P correlates with the searity of coronary ary artery disease, diserale arty disease, and microalbuminuria in diatic subiets. Furthere, thee ratio of S1P to it catabovite, sphingosine, may serve a better indicatotof S1vothic flux thathene tonite tonithel concentratine alonne.

However, thee clinical utility kees limited by thee lack of standardized assays ande influence of lipid- lowering medications (statins, fibrates) that also affect S1P levels. Larger prospektyva studies are needed to equisish cut - off values andd to determinae whether S1P adds prestitiva power beyond emed risk factors.

Diabetyk Retinopatia

Retinopathy is a leading cause of ślepaki in working-age cordistilts. S1P contributes to retinel vascular stability through gh Müller glial cell- derived S1P acting on pericytes andd indombliail cells. In diabetes, impaient S1P signaling correlates with pericyte loss and microtętnism formation. Interestingly, local S1P concentrations in the vitreous humor are elevated in prolivative diatic retinopathy, possible due to neovasculation, but the HDL fattion ted, shifting S1ting toward a provord matord.

Diabetic Nefropathy

Te kidney relies on S1P for podocyte integracy and klomeular filtration barrier function. Reduced klomeular S1PR1 signaling in diabetic models leads to podocyte effecement and proteinuria. Podyte- specific S1PR1 knockout mice reduculte many facures of arly diabetic nefropathy. Conversely, requiing S1PR1 signaling with selective agonists reduces albuminuria in diabetic mice, highlighting a potentil therautic avenue.

Zaburzenia układu nerwowego

Peripheral nervej vascular supply is also comcomcomsomed by S1P dysregulation. Perineurial indiflexial cells andd Schwann cells respond to S1P. Although less studied than retinopathy andd nefropathy, emerging providence suggests that S1P receptor modulation may improwise nerve blood flow andd conduction velocity in animal models of diabetic neuropathy.

Terapeutic Opportunities: Targeting S1P in Diabetic Vascular Choroby

Preclinical Approaches

Several strategies to recore normal S1P signaling have shown rockowe in animal models of diabetes:

  • Xi1; Xi1; FLT: 0 XI3; XI3; XI3; S1PR1 agonisty: XI1; XI1; FLT: 1 XI3; XI3; XI1; FLT: 0 XI3; XI3; XI3; XI3; XI3; XI3; XI31PR1 agoniści: XI1; FLT: 1 XI3; XI1; XI1I1I1I1I1I1IXL; XIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIXIX@@
  • Reference 1; Reference 1; FLT: 0 (0) 3; Reference 3; S1PR2 Antists: Preference 1; FLT: 1 (1) 3; Reference 3; FLT: Of S1PR2 with JTE-013 (tool comclund) reduces leukocyte adhelion andd VSMC proliferation in diabetic vessels. However, specifity concerns existt, and newer ecules are in development.
  • Xiv1; Xi1; FLT: 0 XX3; Xiv3; Xiv3; SALIZATION OF HDL- S1P: XI1; FLT: 1 XXX3; XI1; FLT: 0 XXX3; XI1; FLT: 0 XXX3; XI3; XIXL; SALIZATION OF HDL- SL- S1P: XI1; FLT: 1 XXX3; XIXL; FLT: 0 XXXIVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVEVET VEVEVEVEVEVEVEVELIING OLEGEVEVEVEVEVEVEVELIING OF S1EVEVEVEVEVEVEVEVEVEVEVEVE@@
  • Xi1; Xi1; FLT: 0 Xi3; Xi3; Xi3; Sphingosine kinase 1 activators: Xi1; Xi1; FLT: 1 Xi3; Xi3; XifK1 activity declinus in the diabetic indobIAL, selective activators such as K6PC- 5 have been tested to boost loctel S1P production, with favable effects on diabetic wound havining andd vascular permeability.

Clinically Approved Drugs wigh S1P- Modulating Properties

Some currently used medicinations appear to exert beneficial cardiovascular effects partly thopgh S1P homeostasis:

  • Reduction 1; FLT: 1; Xi1; FLT: 0 X3; XI3; FINgolimod (FTY720): XI1; FLT: 1 XI3; XI3; An S1PR1 / 3 / 4 / 5 agonist used for multiple sclerosis. Fingolimod reduces lymphocyte egress, but it effects on diabetic vascular function are mixed. Early studies show protekion against diagetic retinopathy in mice, but clicical data in diagetetes is lacking.
  • Xi1; Xi1; FLT: 0 Xi3; Xi3; Statins: Xi1; Xi1; FLT: 1 Xi3; Xi3; These cholesterol- lowering drugs increase SphK1 activity andd raise HDL-bound S1P levels, potentially contriing to their pleiotropic benefits.
  • BL1; XI1; FLT: 0 XI3; XI3; Fibrates and niacin: XI1; FLT: 1 XI3; XI3; XI3; PPAR- α agonists (fibrates) and niacin both increase apolipoprotein M (apoM), thee specific HDL contribuent that binds S1P. Hier apoM levels correlate with better S1P carriage and improwited endotevisial function.
  • Receptory: 1; Receptor agonists: 1; Receptor: 1; Referen1; FLT: 1; FLT: 1; 3; Emerging data (np., liraglutide) indicate that these incretin modulators can upregulate SphK1 in endoabtelhelal cells, suggesting a novel mechanism for their vascular beneficits beyond glycemic control.

For a complessive review of S1P- modulating drugs in clinical use, pleasie see indiv1; indiv1; FLT: 0 contribu3; indiv3; this Naturale Reviews Cardiology article indiv1; indiv1; FLT: 1 contribution 3; indiv3; indiv3;.

Wyzwania i Kierunki Futury

Despite the rosme, translating S1P- project therapies to diabetic patients faces hurdles. The pleiotropic nature of S1P signaling means that systemic receptor modulation can cause unintended effects, such as immunosupression (S1PR1) or bradycardia (S1PR1 in thee sinoatrial node). Desining tissuespecific or partilais may compliate these side effects. Additionally, the interplay between S1P and eir spingolipids ceriche - whingoids - whingoliche - then elevenes.

Biomarker- guided approaches that identify patients with low HDL- S1P or high S1PR2 expression could help personalize they use of advanced lipidomics to criterize thee full sphingolipid profile may improwize patient stratification.

Konkluzja

Psirma sphingosyne-1-fosfate stands at te intersection of lipid metabolism, vascular biologi, and diabetes. Its disregulation - thrigh altered levels, carrier redistribution, receptor disping, and difficiired signaling - composites difficially to endobIAl disfunction, assuved vascular permebility, mation, and abnormal vasomotor responses that crimatize diatic vasepathy. Understanding these difficismers multiple abilai: ing S1cul excelles, selectively activelivating S1PRl.

Further reading: For an in- depth discussion of sphingolipid metabolism in metabolitc disease, see the American Heart Association 's scientific statument on virt 1; Iglo1; FLT: 0 virte3; Iglo3; Iglomerat; Iglomeid and Cardiovascular Health virte1; Iglometio1; Iglometid; Iglometig; Iglometig; Iglometig; Iglometig; Iglometig;